1. Home
  2. ASGI vs PHAR Comparison

ASGI vs PHAR Comparison

Compare ASGI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASGI

abrdn Global Infrastructure Income Fund of Beneficial Interest

N/A

Current Price

$18.92

Market Cap

798.5M

Sector

Finance

ML Signal

N/A

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

N/A

Current Price

$11.54

Market Cap

793.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASGI
PHAR
Founded
N/A
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
798.5M
793.4M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
ASGI
PHAR
Price
$18.92
$11.54
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $35.70
AVG Volume (30 Days)
★ 221.9K
14.4K
Earning Date
01-01-0001
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$2.98
Revenue Next Year
N/A
$8.95
P/E Ratio
★ N/A
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$18.90
$9.11
52 Week High
$25.95
$21.34

Technical Indicators

Market Signals
Indicator
ASGI
PHAR
Relative Strength Index (RSI) 31.10 47.19
Support Level $18.92 $9.37
Resistance Level $19.69 $13.50
Average True Range (ATR) 0.47 0.46
MACD -0.13 -0.17
Stochastic Oscillator 3.65 9.59

Price Performance

Historical Comparison
ASGI
PHAR

About ASGI abrdn Global Infrastructure Income Fund of Beneficial Interest

abrdn Global Infrastructure Income Fund is a non-diversified, closed-end management investment company. Its objective is to seek to provide a high level of total return with an emphasis on current income by investing in assets that provide necessary services to society.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: